48,873
edits
Difference between revisions of "Talk:Programmed death-ligand 1"
Jump to navigation
Jump to search
Talk:Programmed death-ligand 1 (view source)
Revision as of 13:16, 17 February 2018
, 13:16, 17 February 2018no edit summary
| Line 7: | Line 7: | ||
*2018 paper: ~ 70% durable response among those that discontinue d/t side effects[https://www.ncbi.nlm.nih.gov/pubmed/29437040] | *2018 paper: ~ 70% durable response among those that discontinue d/t side effects[https://www.ncbi.nlm.nih.gov/pubmed/29437040] | ||
*2018 paper: response rates are low in UCC and RCC, current PD-L1 tests not useful in UCC and RCC[https://www.ncbi.nlm.nih.gov/pubmed/29368638] | *2018 paper: response rates are low in UCC and RCC, current PD-L1 tests not useful in UCC and RCC[https://www.ncbi.nlm.nih.gov/pubmed/29368638] | ||
*2018 meta-analysis: PD-L1 is a poor prognosticator in RCC (HR~2.76)[https://www.ncbi.nlm.nih.gov/pubmed/29362922] | |||
==References== | ==References== | ||
{{Reflist|1}} | {{Reflist|1}} | ||